Growth Hormone Drives Breast Cancer Spread and Blood Vessel Growth
Background
Breast cancer is a complex disease influenced by various factors, with steroid hormones like estrogen being well-known contributors. However, growth hormone (GH) also plays a substantial, often underappreciated, role in its development and spread. This paper synthesizes existing knowledge to fully understand the mechanisms by which GH promotes breast cancer progression and metastasis.
Study Design
Results
The review highlights that breast cancer patients frequently exhibit elevated levels of both growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in their circulation, suggesting a systemic link. Activation of the Growth Hormone Receptor (GHR) signaling pathway is consistently shown to enhance the migratory ability of tumor cells, a key step in metastasis. Furthermore, excess production of IGF-1, often stimulated by GH, directly promotes angiogenesis (the formation of new blood vessels), which is vital for tumor growth and nutrient supply. This dual action of GH on cell migration and vascularization underscores its significant contribution to tumor progression. The paper establishes that growth hormone receptor (GHR) signaling significantly enhances the migratory capacity of breast cancer cells, directly contributing to metastasis.
Why It Matters
This synthesis of evidence underscores the critical role of growth hormone (GH) in driving breast cancer progression, metastasis, and angiogenesis, moving beyond the traditional focus on steroid hormones. Understanding these specific mechanisms opens new avenues for therapeutic intervention. Targeting the GH-IGF-1 axis could lead to novel treatments for advanced breast cancer, potentially inhibiting tumor spread and growth. Future research should focus on developing specific inhibitors for GHR or IGF-1 signaling, paving the way for preclinical and potentially human trials.